EU MDR Annex XVI Non-medical Products

Start with the Annex XVI list, then check whether the product is inside the narrower common-specification scope. The MDR list covers contact lenses or other items introduced into or onto the eye; surgically invasive products for modifying anatomy or fixing body parts, excluding tattooing products and piercings; dermal or mucous membrane fillers introduced by injection or similar methods, excluding tattooing; equipment for reducing, removing, or destroying adipose tissue; high intensity electromagnetic radiation equipment used on the body for skin resurfacing, tattoo or hair removal, or other skin treatment; and brain-stimulation equipment applying electrical currents or magnetic or electromagnetic fields through the cranium.

The common specifications do not cover every edge case in those broad headings. Regulation (EU) 2022/2346 states, for example, that contact lenses containing tools such as antennae or microchips, active contact lenses, active implantable anatomy-modification products, active dermal filling devices, active implantable adipose-tissue equipment, and some other eye products were not covered because the Commission did not have enough market information or sufficient basis for specifications. Sunbeds and infrared warming equipment for treatment under the skin are also carved out of the skin-treatment common specifications.

Implementing Regulation (EU) 2022/2346 makes the Annex I common specifications apply across the covered Annex XVI groups, then adds product-specific annexes for contact lenses, surgically invasive anatomy-modification products, dermal fillers, adipose-tissue equipment, high intensity electromagnetic radiation skin-treatment equipment, and non-invasive brain-stimulation equipment. The shared requirements focus on risk-management planning, hazard analysis, risk evaluation, risk control, residual-risk review, production and post-production information, and safety information for users and consumers.

Before release, the risk-management review needs to show that the planned process was followed, residual risk is acceptable, and the system for collecting production and post-production information is implemented. Labels and instructions for use must avoid clinical-benefit claims for a solely non-medical purpose, state the non-medical purpose, explain expected performance, identify residual risks and control measures, and reference applied harmonised standards and common specifications.

Annex XVI products still need MDR qualification, classification, the applicable conformity-assessment route under Article 52, technical documentation, clinical evaluation, and, where required by the route, notified-body involvement.

For active products, check Implementing Regulation (EU) 2022/2347 before using the Annex VIII fallback. High-intensity electromagnetic radiation equipment for skin treatment is class IIb, except equipment intended only for hair removal is class IIa. Equipment for reducing, removing, or destroying adipose tissue is class IIb. Brain-stimulation equipment covered by Annex XVI point 6 is class III.

Clinical evaluation for these products addresses non-medical performance and safety. Regulation (EU) 2022/2346 says it is based on relevant clinical data, including PMS, PMCF, and, where applicable, clinical investigation. MDCG 2023-6 adds that equivalence can be assessed between products without an intended medical purpose using MDR technical, biological, and clinical characteristics adapted to the non-medical purpose, but a comparison with an analogous medical device is generally not possible because the medical-device clinical-condition criteria cannot be completed.

Do not assume that every Annex XVI product had to complete its full MDR route on the common-specification application date. Implementing Regulation (EU) 2023/1194 extended conditional transitions for products that need a clinical investigation or notified-body conformity assessment and aligned some products previously covered by an MDD certificate with the amended MDR legacy-device dates.

For the clinical-investigation route, the product must have been lawfully marketed in the Union before 22 June 2023, remain compliant with the earlier applicable law, and have no significant design or intended-purpose change. For placement from 23 December 2024 through 31 December 2027, the sponsor must have started the clinical investigation; from 1 January 2028, a written notified-body conformity-assessment agreement is required. That route ends on 31 December 2029. The no-clinical-investigation route has the same pre-22 June 2023 and no-significant-change conditions, requires a written notified-body agreement for placement from 1 January 2027, and ends on 31 December 2028. A prior MDD certificate route instead depends on the applicable MDR Article 120 conditions and category date.

The post-launch system is part of the pre-launch evidence. The MDR expects manufacturers to operate a quality management system, risk management, PMS, and reporting of incidents and field safety corrective actions. Regulation (EU) 2022/2346 also requires production and post-production information to feed back into the risk-management file, including new hazards, unacceptable residual risks, and actions for products already made available on the market.

Traceability evidence should cover UDI assignment and device registration where the applicable route requires them. Since 28 May 2026, the EUDAMED Actor, UDI/Devices, Notified Bodies and Certificates, and Market Surveillance modules have been mandatory; the Clinical Investigations and Vigilance/PMS modules remain on separate later milestones. Apply the MDR exceptions and legacy-device rules rather than assuming every Annex XVI product follows the standard UDI/device workflow.

A launch-ready Annex XVI file should let a reviewer trace the conclusion from product facts to legal scope, common specifications, risk controls, clinical evidence, conformity assessment, labelling, and post-market obligations. The pack should be specific enough that a product variant, professional-use claim, lay-use claim, or body-site change cannot silently inherit old evidence.

Use the pack as a release gate. If a fact is missing, mark the item blocked rather than filling the gap with a broad MDR statement.